A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. (September 2022)
- Record Type:
- Journal Article
- Title:
- A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. (September 2022)
- Main Title:
- A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults
- Authors:
- Osadnik, Tadeusz
Goławski, Marcin
Lewandowski, Piotr
Morze, Jakub
Osadnik, Kamila
Pawlas, Natalia
Lejawa, Mateusz
Jakubiak, Grzegorz K.
Mazur, Agnieszka
Schwingschackl, Lucas
Gąsior, Mariusz
Banach, Maciej - Abstract:
- Abstract: It is estimated that 2.6 million deaths worldwide can be attributed to hypercholesterolemia. The main reason for non-adherence to statin therapy are the statin-associated muscle symptoms (including nocebo/drucebo effect). In this case, apart from ezetimibe, nutraceuticals are prescribed. We aimed to assess the comparative efficacy of different nutraceuticals in terms of lowering low density lipoprotein cholesterol (LDL-C) and improving lipid profile. Electronic and hand searches were performed until February 2021. The inclusion criteria were the following: (1) randomized trial with any of the reportedly LDL-C lowering nutraceutical: artichoke, berberine, bergamot, garlic, green tea extract, plant sterols/stanols, policosanols, red yeast rice (RYR), silymarin or spirulina. (2) outcome either LDL-C (primary outcome), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) or serum triglycerides (TG). Random effects network meta-analysis (NMA) was performed to rank the effect of each intervention using frequentist approach. Finally, a total of 131 trials enrolling 13, 062 participants were included. All analysed nutraceuticals except for policosanols were more effective in lowering LDL-C (−1.21 [−46.8 mg/dL] to −0.17 [−6.6 mg/dL] mmol/l reduction) and TC (−1.75 [−67.7 mg/dL] to −0.18 [7 mg/dL] mmol/l reduction) than placebo/no intervention. The most effective approaches in terms of LDL-C- and TC-lowering were bergamot and RYR (−1.21 [−46.8 mg/dl] andAbstract: It is estimated that 2.6 million deaths worldwide can be attributed to hypercholesterolemia. The main reason for non-adherence to statin therapy are the statin-associated muscle symptoms (including nocebo/drucebo effect). In this case, apart from ezetimibe, nutraceuticals are prescribed. We aimed to assess the comparative efficacy of different nutraceuticals in terms of lowering low density lipoprotein cholesterol (LDL-C) and improving lipid profile. Electronic and hand searches were performed until February 2021. The inclusion criteria were the following: (1) randomized trial with any of the reportedly LDL-C lowering nutraceutical: artichoke, berberine, bergamot, garlic, green tea extract, plant sterols/stanols, policosanols, red yeast rice (RYR), silymarin or spirulina. (2) outcome either LDL-C (primary outcome), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) or serum triglycerides (TG). Random effects network meta-analysis (NMA) was performed to rank the effect of each intervention using frequentist approach. Finally, a total of 131 trials enrolling 13, 062 participants were included. All analysed nutraceuticals except for policosanols were more effective in lowering LDL-C (−1.21 [−46.8 mg/dL] to −0.17 [−6.6 mg/dL] mmol/l reduction) and TC (−1.75 [−67.7 mg/dL] to −0.18 [7 mg/dL] mmol/l reduction) than placebo/no intervention. The most effective approaches in terms of LDL-C- and TC-lowering were bergamot and RYR (−1.21 [−46.8 mg/dl] and −0.94 [−36.4 mg/dl] mmol/l) reduction respectively. In conclusion, bergamot and RYR appear to be the most effective nutraceuticals in terms of LDL-C and TC reduction. Evidence for bergamot effect was based on relatively small study group and may require further investigations. Policosanols have no effect on the lipid profile. Graphical Abstract: ga1 … (more)
- Is Part Of:
- Pharmacological research. Volume 183(2022)
- Journal:
- Pharmacological research
- Issue:
- Volume 183(2022)
- Issue Display:
- Volume 183, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 183
- Issue:
- 2022
- Issue Sort Value:
- 2022-0183-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-09
- Subjects:
- Lipid-lowering therapy -- Meta-analysis -- Natural products -- Nutraceuticals -- Statins
Pharmacology -- Periodicals
Pharmacology -- Periodicals
Research -- Periodicals
Médicaments -- Recherche -- Périodiques
Pharmacologie -- Périodiques
615.105 - Journal URLs:
- http://www.sciencedirect.com/science/journal/10436618 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.phrs.2022.106402 ↗
- Languages:
- English
- ISSNs:
- 1043-6618
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.550000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23289.xml